SG Americas Securities LLC Buys Shares of 21,387 Enovis Corporation $ENOV

SG Americas Securities LLC purchased a new stake in Enovis Corporation (NYSE:ENOV) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 21,387 shares of the company’s stock, valued at approximately $649,000.

Other institutional investors have also recently made changes to their positions in the company. McIlrath & Eck LLC lifted its holdings in Enovis by 6.9% in the third quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock valued at $167,000 after acquiring an additional 357 shares during the last quarter. Farther Finance Advisors LLC raised its position in Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after purchasing an additional 367 shares during the period. Teacher Retirement System of Texas lifted its stake in shares of Enovis by 6.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock valued at $272,000 after purchasing an additional 495 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Enovis by 2.7% during the 2nd quarter. Janney Montgomery Scott LLC now owns 22,375 shares of the company’s stock worth $702,000 after purchasing an additional 593 shares during the period. Finally, Heritage Family Offices LLP grew its holdings in shares of Enovis by 8.9% during the 3rd quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock worth $231,000 after purchasing an additional 620 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

ENOV has been the topic of several research analyst reports. BTIG Research assumed coverage on shares of Enovis in a report on Tuesday, January 6th. They issued a “buy” rating and a $41.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th. UBS Group reissued a “buy” rating and issued a $50.00 price target on shares of Enovis in a research note on Monday, January 5th. Canaccord Genuity Group lowered their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Finally, Wells Fargo & Company lifted their target price on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Insider Buying and Selling at Enovis

In related news, insider John Kleckner bought 2,468 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was purchased at an average cost of $30.32 per share, with a total value of $74,829.76. Following the purchase, the insider directly owned 12,302 shares of the company’s stock, valued at $372,996.64. This trade represents a 25.10% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The disclosure for this sale is available in the SEC filing. Insiders own 2.70% of the company’s stock.

Enovis Stock Down 0.6%

Shares of ENOV opened at $23.53 on Friday. The stock has a market capitalization of $1.35 billion, a PE ratio of -0.99 and a beta of 1.52. Enovis Corporation has a 1 year low of $22.98 and a 1 year high of $49.38. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The company’s 50-day simple moving average is $27.23 and its 200-day simple moving average is $29.39.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The firm had revenue of $548.91 million during the quarter, compared to analysts’ expectations of $538.61 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. Analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.